Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-04-30

Development of a dna vector for the treatment of haemophilia a using gene therapy technologies

Objetivo



Current treatment regimes for Haemophilia A involve the frequent administration of plasma derived or recombinant human Factor VIII (hFVIII). However, treatment is restricted by the availability, short half-life and high cost of purifled hFVIII. Therefore, we propose to develop a clinical gene therapy protocol suitable for the treatment of patients suffering from Haemophilia A.
To achieve this we propose to assess a number of eukaryotic promoters for cell type specificity in addition to persistence of on in lineages derived from hematopoietic stem cells. These promoters will then be transferred into a retroviral backbone where they will regulate expression of the hFVIII cDNA. Hematopoietic cells will be obtained from patients bone marrow, transduced in vitro, prior to reimplantation into the patients. Peripheral blood cells derived from the transduced hematopoietic stem cells are expected to secrete hFvIII directly into the plasma resulting in the systemic correction of the condition.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

Datos no disponibles

Régimen de financiación

RGI - Research grants (individual fellowships)

Coordinador

KAROLINSKA INSTITUTE
Aportación de la UE
Sin datos
Dirección
Haelsvaegen 7
141 57 Huddinge
Suecia
Coste total
Sin datos

Participantes (1)